Curriculum Vitae
David J. Grdina
CURRICULUM VITAE
NAME:
EDUCATION:
DAVID J. GRDINA
University of Houston
Houston, Texas
M.B.A.
(Finance)
1980
University of Kansas
Lawrence, Kansas
Ph.D.
(Radiation Biophysics)
1971
University of Kansas
Lawrence, Kansas
M.S.
(Radiation Biophysics)
1969
St. Mary's College
Winona, Minnesota
B.A.
(Biology)
1966
Section of Experimental Biology
The University of Texas System
Cancer Center, M.D. Anderson
Hospital and Tumor Institute,
Houston, Texas
Postdoctoral Fellow
in Biology
March 1971 May 1972
Professor of Radiation
and Cellular Oncology
July 1987Present
Associate Professor of
Radiation and Cellular
Oncology
Jan. 1985 June 1987
University of Chicago
Cancer Research Center
Co-Program Leader
Chemoprevention
Oct. 1994 July 2000
Center for Mechanistic Biology
and Biotechnology
(formerly, Biological and Medical
Research Division)
Argonne National Laboratory,
Argonne, Illinois
Head, Section of
Radiation Biology
Nov. 1991 Sept. 1996
Senior Scientist,
Group Leader,
Radiation Carcinogenesis
(Joint Appt. U. of C.)
June 1987 Sept. 1996
Scientist, Group Leader,
Radiation Carcinogenesis
Sept. 1983 June 1987
Adjunct Associate
April 1984 -
PROFESSIONAL EXPERIENCE:
Department of Radiation and Cellular
Oncology, The University of Chicago
Chicago, Illinois
Department of Therapeutic Radiology,
1
Curriculum Vitae
Rush Medical College, RushPresbyterian-St. Luke's Medical Center,
Chicago, Illinois
Department of Experimental
Radiotherapy, The University
of Texas System Cancer Center,
M.D. Anderson Hospital and
Tumor Institute, Houston, Texas
Baylor College of Medicine and
St. Luke's Episcopal Hospital
Houston, Texas, in conjunction
with University of Houston
School of Nuclear Medicine
Technology
David J. Grdina
Professor
March 1985
Associate Biologist and
Associate Professor of
Radiotherapy (Biology)
Sept. 1978 Sept. 1983
Assistant Biologist and
Assistant Professor of
Radiotherapy (Biology)
Sept. 1975 Aug. 1978
Research Associate
June 1972 Aug. 1975
Visiting Lecturer
Biological Effects
of Nuclear Medicine
June-Aug. 1976
Sept. 1983
PROFESSIONAL CONSULTANTSHIPS:
National Institutes of Health
Bethesda, MD
Consultant
Radiation Study Section
Reviewers Reserve
National Cancer Institute
NCI Discovery and
Development P01
2007-present
HollisEden
Consultant
2004-2007
Pinnacle Biologics
Consultant
2009-present
Congressional Pharmaceuticals
Corporation
Founding Scientist
2001-2004
PrevOnc (Prevention of Oncogenesis)
Founding Scientist
1999-2001
Radiation Oncology Modifiers
Corporation (ROMCOR)
Founding Scientist
1997-1998
Odyssey Therapeutics
3461 Route 22 East
Somerville, NJ 08876
Member: Scientific
and Medical Advisory
Board
1993-1996
2
1990-1994
1994-present
Curriculum Vitae
U.S. Bioscience
One Tower Bridge
100 Front Street, P.O. Box 851
West Conshohocken, PA 19428
David J. Grdina
Member: Basic
Science Advisory
Board
Consultant
1993-1994
1999-2000
Microfocus Imaging
225 Larkin Drive
Wheeling, IL 60090
Consultant
Product Development
1992-1995
Schering-Plough International
Ethyol Speaker Bureau
Speaker
1996-2001
ALZA Pharmaceuticals Ethyol
Speakers Bureau
Speaker
1996-2001
MedImmune Speakers Bureau
Speaker
2001-2004
NIH STUDY SECTIONS:
NIH Special Study Section
Member
1989
NIH Radiation Study Section
Ad Hoc Member
1990
NIH Radiation Study Section
Member
1990 - 1994
NIH Reviewers Reserve
Member
1994 - present
NCI Initial Review Group
Committee-Subcommittee C Basic and Preclinical Sciences
Member
1996 - 2000
NCI Initial Review Group
Committee-Subcommittees A,
D, and E
Ad Hoc Member
1998 -
NCI Special Emphasis Panel
Ad Hoc Member
2007-present
Department of Energy
Ad Hoc Member
1983 - 1995
Veterans Administration
Ad Hoc Member
1987 - present
American Cancer Society
(Illinois Division, Inc.)
Member
1991 - 1992
Koningin Wilhelmina Fonds
Netherlands Cancer Foundation
Ad Hoc Member
1985 - present
GRANT REVIEWER:
3
Curriculum Vitae
David J. Grdina
MEMBERSHIP ON COMMITTEES:
National
NASA Space Radiation Standing Review
Panel, Human Research Program
Member
2009-present
AERAS Global TB Vaccine Foundation
Institutional BioSafety Committee
Member
2006-present
NIH/NCI Radiation Carcinogenesis
Workshop
Chairperson and
Organizer
2006
Blue Ribbon Panel for NIH Strategic
Plan and Research Agenda for Medical
Countermeasures Against Radiological
And Nuclear Threats.
Member
2004
Radiation Research Society
Fundraising Committee
Member
1997 - 1998
Radiation Research Society
Policies and Procedures Committee
Member
1993-1996
Radiation Research Society
Program Committee
42nd Annual Meeting
Member
1993 - 1994
BEVALAC Biomedical Program
Advisory Committee,
Lawrence Berkeley Laboratory
Member
1991 - 1992
Radiation Research Society
Executive Committee
Member
1989 - 1993
Radiation Research Society
Finance Committee
Chairman
1982 - 1985
Radiation Research Society
Management Support Contract
Committee
Member
1985 - 1987
Radiation Research Society
Ad Hoc Subcommittee on
Society Journal
Member
1982 - 1987
The Cell Kinetics Society
Finance Committee
Member
1982 - 1984
4
Curriculum Vitae
David J. Grdina
Local
Nuclear Incident and Radiation
Member
Dispersal Device Committee; Subcommittee
Of the ITTF Science and Technology Committee
For The State of Illinois
2003-2006
University of Chicago Cancer Research
Center Executive Committee
Member
1994 - 2004
University of Chicago Committee on
Appointments and Promotions (COAP)
Member
2000 – 2004
2009-present
University of Chicago Committee on
Radioactive Use
Member
2000 - 2006
University of Chicago Committee on
Cancer Biology
Member
1994 - Present
Argonne National Laboratory
BIM Division, Library Committee
Member
1984 - 1991
Argonne National Laboratory
BIM Division, Animal Use Committee
Member
1985 - 1987
Argonne National Laboratory
BIM Division, Human Use Committee
Member
1988 - 1995
Argonne National Laboratory
BIM Division, Promotions Committee
Member
1989 - 1992
Argonne National Laboratory
BIM Division, Enrico Fermi
Fellowship Committee
Chairman
1989 - 1996
Argonne National Laboratory
BIM Division, Seminar Committee
Chairman
1990 - 1991
Argonne National Laboratory
EEST Personnel Oversight Committee
on Hiring and Promotions
Member
1992 - 1994
Argonne National Laboratory
Performance Appraisal Task Force,
Scientific/Engineering
Performance Appraisal Task Force
Member
5
1993 - 1996
Curriculum Vitae
David J. Grdina
Argonne National Laboratory
Working Group to Explore Scientific
Relationship between The University
of Chicago and Argonne National
Laboratory in Medical Sciences.
Member
1993 - 1995
The University of Texas Graduate
School of Biomedical Sciences,
Houston, Texas,
Advisory, Supervisory, and/or
Candidacy Examining Committees
Member of committees
for six students
1975 - 1983
The University of Texas
System Cancer Center
Academic Standards Committee
Member
Jan. 1977 - 1980
M.D. Anderson Hospital and
Tumor Institute,
Ad Hoc Task Force on Extramural
Impact in FY 82 Academic Plan
Member
1981 - 1982
The University of Texas
M.D. Anderson Hospital,
Research Committee
Member at Large
1981 - 1983
EDITORIAL BOARD:
Associate Editor representing Biology;
Radiation Research Journal
1986 – 1990
Advisory Board Member; CRC Critical
Reviews in Sulfhydryl Biochemistry
1988 - 1989
Advisory Board Member; Libri Oncologici
(Cancer Journal published in English and Croatian)
1992 - present
Member of the Overseas Editorial Board, Journal
of Radiation Research (Japanese Journal)
2000-2005
MEMBERSHIP IN SCIENTIFIC SOCIETIES:
Radiation Research Society
American Association for Cancer Research
University of Texas M. D. Anderson Associates (founding member)
ELECTED OFFICE:
Secretary/Treasurer,
Radiation Research Society
1989 - 1993
6
Curriculum Vitae
David J. Grdina
VISITING SCIENTISTS/POSTDOCTORALS TRAINED:
Dr. Curt Sigdestad
University of Louisville
Dr. Biba Nagy
Science Advisor to the President
of the Republic of Croatia
Zagreb, Croatia
Dr. Paul Meechan
Northern Illinois University
Dr. Ivan Basic
University of Zagreb
Zagreb, Croatia
Dr. Andrew Vaughan
University of Birmingham
Birmingham, England
Dr. Yasushi Kataoka
National Institute of Radiological Sciences
Chiba, Japan
Dr. Naoyuki Shigematsu
Keio University
Tokyo, Japan
Dr. Barton Bergquist
University of Northern Iowa
Dr. Coral Quiet
University of Chicago
Dr. Jeff Murley
Northern Illinois University
Dr. Shie-Chau Liu
Illinois Institute of Technology
Dr. William Epperly
Argonne National Laboratory
HONORS:
Atomic Energy Commission Special Health Physics Fellowship,
University of Kansas, Sept. 1966 - Aug. 1967.
United States Public Health Service Traineeship in Health Physics,
University of Kansas, Sept. 1968 - Feb. 1971.
7
Curriculum Vitae
David J. Grdina
AWARDS:
6th International Congress for Radiation Research (ICRR) Travel Award,
1979; 7th ICRR Travel Award, 1983; 8th ICRR Travel Award, 1987; 10th ICRR Travel
Award, 1995
Japanese Government Research Award for Foreign Specialists, 1988.
John Yuhas Award for Excellence in Research,
University of Pennsylvania, 1993.
PROFESSIONAL LISTINGS:
Marquis Who's Who in Cancer Professionals and Facilities, 1st Ed., 1985.
American Men and Women of Science, Physical and Biological Sciences,
16th Ed., 1986.
Marquis Who's Who in the Midwest, 23rd Ed., 1991.
PATENTS
U.S. Patents: “Method for Protection Against Genotoxic Mutagenesis,” 5,488,042, issued
January 30, 1996.U.S. Patent 5,567,686, issued October 22, 1996. U.S. Patent 5,869,338, issued
February 9, 1999. U.S. Patent 5,891,856, issued April 6, 1999.
“Method for Protection Against Tumor Metastasis Formation. U.S. Patent 6,984,619, 2006.
8
Curriculum Vitae
I.
PEER REVIEWED JOURNAL ARTICLES
David J. Grdina
1.
Grdina, D.J., P. Lohman, and R.R. Hewitt. A Fluorometric Method for the Detection of
Endodeoxyribonuclease on DNA-Polyacrylamide Gels. Analytical Biochemistry, 51:255-264, #1,
January, 1973.
2.
Grdina, D.J., L. Milas, R.R. Hewitt, and H.R. Withers. Buoyant Density Separation of Human
Blood Cells in Renografin Gradients. Experimental Cell Research, 81:250-254, 1973.
3.
Grdina, D.J., L. Milas, K. Mason, and H.R. Withers. Separation of Cells from a Fibrosarcoma in
Renografin Gradients. Journal of the National Cancer Institute, 52:253-257, #1, January, 1974.
4.
Grdina, D.J., M. Meistrich, and H.R. Withers. Separation of Clonogenic Cells from Stationary
Phase Cultures by Density Gradient Centrifugation. Experimental Cell Research, 85:15-22, 1974.
5.
Basic, I., L. Milas, D. Grdina, and H.R. Withers. Destruction of Hamster Ovarian Cell Cultures by
Peritoneal Macrophages from Mice Treated with Corynebacterium granulosum. Journal of the
National Cancer Institute, 52:1839-1842, June, 1974.
6.
Milas, L., N. Hunter, I. Basic, K. Mason, D.J. Grdina, and H.R. Withers. Nonspecific
Immunotherapy of Murine Solid Tumors with C. granulosum. Journal of the National Cancer
Institute, 54:895-902, 1975.
7.
Basic, I., L. Milas, D.J. Grdina, and H.R. Withers. In vitro Destruction of Tumor Cells by
Macrophages from Mice Treated with C. granulosum. Journal of the National Cancer Institute,
55:589-596, 1975.
8.
Grdina, D.J., I. Basic, K. Mason, and H.R. Withers. Radiation Response of Clonogenic Cell
Populations Separated from a Fibrosarcoma. Radiation Research, 63:483-493, 1975.
9.
Grdina, D.J., I. Basic, S. Guzzino, and K.A. Mason. Radiation Response of Cell Populations
Irradiated in situ and Separated from a Fibrosarcoma. Radiation Research, 66:634-643, 1976.
10.
Grdina, D.J., W.H. Hittleman, A. White, and M.L. Meistrich. The Formation of Lung Colonies. An
Analysis Based on Cellular Parameters of Density, Size, and DNA Content. British Journal of
Cancer, 36:659-669, 1977.
11.
Suzuki, N., M. Frapart, D.J. Grdina, M.L. Meistrich, and H.R. Withers. Cell Cycle Dependency of
Metastatic Lung Colony Formation. Cancer Research, 37:3690-3693, October, 1977.
12.
Meistrich, M.L., D.J. Grdina, R.E. Meyn, and B. Barlogie. Separation of Cells from Mouse Solid
Tumors by Centrifugal Elutriation. Cancer Research, 37:4291-4296, December, 1977.
13.
Grdina, D.J., S. Linde, and K. Mason. Response of Selected Tumor Populations Separated from a
Fibrosarcoma Following Irradiation in situ with Fast Neutrons. British Journal of Radiology, 51:291301, March, 1978.
14.
Grdina, D.J., L.J. Peters, S. Jones, and E. Chan. Separation of Cells from a Murine Fibrosarcoma on
the Basis of Size. I. Relationship Between Cell Size and Age as Modified by Growth in vivo or in
vitro. Journal of the National Cancer Institute, 61:209-214, July, 1978.
9
Curriculum Vitae
David J. Grdina
15.
Grdina, D.J., L.J. Peters, S. Jones, and E. Chan. Separation of Cells from a Murine Fibrosarcoma on
the Basis of Size. II. Differential Effects of Cell Size and Age on Lung Retention and Colony
Formation in Normal and Pre-Conditioned Mice. Journal of the National Cancer Institute, 61:215220, July 1978.
16.
Grdina, D.J., C.P. Sigdestad, and L.J. Peters. Phase Specific Cytotoxicity in vivo of Hydroxyurea on
Murine Fibrosarcoma Cells Synchronized by Centrifugal Elutriation. British Journal of Cancer,
39:152-159, February, 1979.
17.
Grdina, D.J., C.P. Sigdestad, and J.A. Jovonovich. Cytotoxic Effect of Adriamycin in vivo on
Synchronized Murine Fibrosarcoma Cells. International Journal of Radiation Oncology, Biology,
Physics, 5:1305-1308, 1979.
18.
Sigdestad, C.P., D.J. Grdina, and K. Ando. Density Gradient Centrifugation of Cells Separated from
Multicellular Tumor Spheroids. Experentia, 35/6:815-817, 1979.
19.
Hunter, N., L.J. Peters, D.J. Grdina, R.A. White, and A. Bartel. Radiation Sensitivity of Murine
Fibrosarcoma Cells Separated by Centrifugal Elutriation. Radiation Research, 80:389-397, 1979.
20.
Grdina, D.J., C.P. Sigdestad, and J.A. Jovonovich. The Effect of Misonidazole in situ on the
Radiation Response of Selected Tumor Cell Subpopulations. Clinical Cancer Trials, 3:149-154,
1980.
21.
Sigdestad, C.P., and D.J. Grdina. Velocity Sedimentation of Tumor Cells: A Comparison of
Methods. Experentia, 37:501-502, 1981.
22.
Sigdestad, C.P., and D.J. Grdina. In vivo Cell Cycle Phase Preferential Killing of Murine
Fibrosarcoma Cells by Cis-Dichlorodiammine Platinum II. Cancer Treatment Reports, 65:845-851,
1981.
23.
Sigdestad, C.P., and D.J. Grdina. Density Centrifugation of Murine Fibrosarcoma Cells Following
in situ Labeling with Tritiated Thymidine. Cell Tissue Kinetics, 14:589-600, 1981.
24.
Grdina, D.J. Phase-Specific Cytotoxicity in vivo of Hydroxyurea on Murine Fibrosarcoma
Pulmonary Nodules. British Journal of Cancer, 45:438-446, 1982.
25.
Grdina, D.J., and N. Hunter. Cyclic-Radiation Response of Murine Fibrosarcoma Cells Grown as
Pulmonary Nodules. International Journal of Radiation Oncology, Biology, Physics, 8:1727-1734,
1982.
26.
Brock, W.A., D.E. Swartzendruber, and D.J. Grdina. Studies of the Kinetic Heterogeneity in
Density Separated Tumor Subpopulations. Cancer Research, 42:4999-5003, 1982.
27.
Mian, T.A., J.C. Theiss, and D.J. Grdina. Lung Tumorigenic Response of Strain A Mice Exposed to
Hypoxic Cell Sensitizers Alone and in Combination with Gamma Radiation. Cancer Research,
43:146-149, 1983.
10
28.
Curriculum Vitae
David J. Grdina
Thames, H.D., D.J. Grdina, and L. Milas. Response of a Fibrosarcoma Cell Population to Small
Doses of Radiation Delivered in situ. International Journal of Radiation Oncology, Biology,
Physics, 9:217-220, 1983.
29.
Grdina, D.J., and R.A. White. Treatment of Artificially-Induced Pulmonary Metastases with
Fractionated Doses of Vincristine and/or Radiation Therapy. Clinical and Experimental Metastasis,
1:71-81, 1983.
30.
Grdina, D.J., R.A. White, and J.J. Stragand. Cytotoxic Effects of Vincristine on Tumor
Subpopulations Separated from Pulmonary Nodules. British Journal of Cancer, 48:279-287, 1983.
31.
Grdina, D.J., and G. Zin. Density Gradient Centrifugation of Tumor Cells from Needle Biopsies and
Their Respective Source Tumors: A Comparison of Density Distributions. Experentia, 39:916-917,
1983.
32.
Grdina, D.J., M.L. Meistrich, R.E. Meyn, T.S. Johnson, and R.A. White. Cell Synchrony
Techniques. I. A Comparison of Methods. Cell and Tissue Kinetics, 17:223-236, 1984.
33.
White, R.A., D.J. Grdina, M.L. Meistrich, R.E. Meyn, and T.S. Johnson. Comparison of Cell
Synchrony Techniques. II. Cell Progression Data. Cell and Tissue Kinetics, 17:237-245, 1984.
34.
Grdina, D.J., H.D. Thames, and L. Milas. Tumor Sensitizing Effect by Misonidazole in a Clinically
Relevant Radiation Dose Range. International Journal of Radiation Oncology Biology, Physics,
10:379-383, 1984.
35.
Grdina, D.J., S. Jones, and N. Hunter. Effectiveness of AMSA Alone or in Combination with
Radiation on Murine Fibrosarcoma Pulmonary Nodules. Clinical and Experimental Metastasis,
2:223-233, 1984.
36.
Grdina, D.J., B. Nagy, C.K. Hill, R.L. Wells, and C. Peraino. The Radioprotector WR1065 Reduces
Radiation-Induced Mutations at the HGPRT Locus in V79 Cells. Carcinogenesis, 6:929-931, 1985.
37.
Grdina, D.J., C. Peraino, B.A. Carnes, and C.K. Hill. Protective Effect of
[S-2-(3-aminopropylamino) ethyl phosphorothioic acid] Against Induction of Altered Hepatocyte
Foci in Rats Treated Once with Gamma Radiation Within One Day After Birth. Cancer Research,
45:5379-5381, 1985.
38.
Thames, H.D., D.J. Grdina, and L. Milas. On the / Ratio and OER for Clonogenic Tumors Cells.
International Journal of Radiation Oncology, Biology, Physics, Correspondence, 11:1572-1573,
1985.
39.
Nagy, B., P.J. Dale, and D.J. Grdina. Protection Against Cis-Diammine-dichloroplatinum (II)
Cytotoxicity and Mutagenicity in V79 Cells by Free Radical Scavenger 2-[(aminopropyl)amino]
ethanethiol. Cancer Research, 46:1132-1135, 1986.
40.
Peraino, C., D.J. Grdina, and B.A. Carnes. Synergistic Induction of Altered Hepatocyte Foci by
Combined Gamma Radiation and Diethylnitrosamine Administration to Neonatal Rats.
Carcinogenesis, 7:445-448, 1986.
11
41.
Curriculum Vitae
David J. Grdina
Sigdestad, C.P., D.J. Grdina, W.R. Hanson, and A.M. Connor. Comparative Radioprotection from
Three Neutron Sources with WR2721 and WR151327, Radiation Research, 106:224-233, 1986.
42.
Hill, C.K., B. Nagy, C. Peraino, and D.J. Grdina. 2-[(Aminopropyl)amino]ethanethiol (WR1065) is
Anti-neoplastic and Anti-mutagenic When Given During 60Co -ray Irradiation, Carcinogenesis,
7:665-668, 1986.
43.
Nagy, B., and D.J. Grdina. Protective Effects of 2-[(Aminopropyl) Amino] Ethanethiol Against
Bleomycin, Nitrogen Mustard, Cis-Diamminedichloroplatinum, and Radiation Induced Mutagenicity
in V-79 Cells. International Journal of Radiation Oncology, Biology, Physics, 12:1475-1478, 1986.
44.
Grdina, D.J., and B. Nagy. The Effect of 2-[(aminopropyl)amino] Ethanethiol (WR1065) on
Radiation-Induced DNA Damage and Repair and Cell Progression in V79 Cells. British Journal of
Cancer, 54:933-941, 1986.
45.
Peraino, C., D.J. Grdina, E.F. Staffeldt, J.J. Russell, A. Prapuolenis, and B.A. Carnes. Effects of
Separate and Combined Treatments with Gamma Radiation and Diethylnitrosamine in Neonatal Rats
on the Induction of Altered Hepatocyte Foci and Hepatic Tumors. Carcinogenesis, 8:599-600, 1987.
46.
Sigdestad, C.P., S.H. Treacy, L.A. Knapp, and D.J. Grdina. Effects of 2-[(Aminopropyl)amino]
Ethanethiol (WR-1065) on Radiation-Induced DNA Double-Strand Damage and Repair in V79 Cells.
British Journal of Cancer, 55:477-482, 1987.
47.
Hanson, W.R., and D.J. Grdina. Radiation-Induced DNA Single-Strand Breaks in the Intestinal
Mucosal Cells of Mice Treated with the Radioprotectors: WR-2721 or 16-16 Dimethyl Prostaglandin
E2. International Journal of Radiation Biology, 52:67-76, 1987.
48.
Zhang, J., C.P. Sigdestad, M.A. Gemmell, and D.J. Grdina. Modification of Radiation Response in
the Mouse Using Fractionated Extracts of Panax ginseng. Radiation Research, 112:156-163, 1987.
49.
Schwartz, J.L., S.M. Giovanazzi, T. Karrison, C. Jones, and D.J. Grdina. 2-[(Aminopropyl)amino]
Ethanethiol (WR1065)-Mediated Reductions in 60Co Gamma-Ray and Fission-Spectrum NeutronInduced Chromosome Damage in V79 Cells. Radiation Research, 113:145-154, 1988.
50.
Grdina, D.J., B. Nagy, and C.P. Sigdestad. Radioprotectors in Treatment Therapy to Reduce Risk in
Secondary Tumor Induction. Pharmacology and Therapeutics, 39:21-25, 1988.
51.
Grdina, D.J., W.H. Guilford, C.P. Sigdestad, and C.S. Giometti. Effects of Radioprotectors on DNA
Damage and Repair, Proteins, and Cell-Cycle Progression. Pharmacology and Therapeutics, 39:133137, 1988.
52.
Sigdestad, C.P., K.W. Doak, and D.J. Grdina. In Vitro Modification of Radiation Induced DNA
Single-Strand Breaks and Cell Survival by Solcoseryl. Experentia, 44:707-708, 1988.
53.
Sigdestad, C.P., W. Guilford, J. Perrin, and D.J. Grdina. Cell Cycle Redistribution of Cultured Cells
after Treatment with Chemical Radiation Protectors. Cell and Tissue Kinetics, 21:193-200, 1988.
12
54.
Curriculum Vitae
David J. Grdina
Grdina, D.J., C.P. Sigdestad, P.J. Dale, and J.M. Perrin. The Effect of 2-[(Aminopropyl)amino]
Ethanethiol on Fission-Neutron-Induced DNA Damage and Repair. British Journal of Cancer,
59:17- 21, 1989.
55.
Grdina, D.J., B. Nagy, C.K. Hill, and C.P. Sigdestad. Protection Against Radiation-Induced
Mutagenesis in V79 Cells by 2-[(Aminopropyl)amino] Ethanethiol Under Conditions of Acute
Hypoxia. Radiation Research, 117:251-258, 1989.
56.
Grdina, D.J., C.P. Sigdestad, and B.A. Carnes. Protection by WR1065 and WR151326 Against
Fission-Neutron-Induced Mutations at the HGPRT Locus in V79 Cells. Radiation Research,
117:500- 510, 1989.
57.
Nagy, B. and D.J. Grdina. Plasminogen Activator Activity in Clonogenic Cell Populations
Separated from a Murine Fibrosarcoma. Clinical and Experimental Metastasis, 7:243-250, 1989.
58.
Rotmensch, J., R.W. Atcher, R. Schlenker, J. Hines, D. Grdina, B.S. Block, M.F. Press, A.L. Herbst,
and R.R. Weichselbaum. The Effect of the Alpha-Emitting Radionuclide Lead-212 on Human
Ovarian Carcinoma: A Potential New Form of Therapy. Gynecologic Oncology, 32:236-239, 1989.
59.
Atcher, R., J. Mitchell, J. Hines, J. Rotmensch, D.J. Grdina. Halogenated Pyrimidines as
Radiosensitizers for High-LET Radiation. Radiation Research, 117:351-355, 1989.
60.
Ando, K., H. Ohara, S. Matsushita, S. Koike, S. Furukawa, and D.J. Grdina. Radioprotection from
Fast Neutron Irradiation by WR151327. Inst. Phys. Chem. Res., 83:40-41, 1989.
61.
Rotmensch, J., R.W. Atcher, J. Hines, D.J. Grdina, J.L. Schwartz, M. Toohill and A.L. Herbst. The
development of Alpha-Emitting Radionuclide Lead-212 for the Potential Treatment of Ovarian
Carcinoma. American Journal of Obstetrics and Gynecology, 160:789-797, 1989.
62.
Vaughan, A.T.M., D.J. Grdina, P.J. Meechan, A.E. Milner and D.J. Gordon. Conformational
Changes in Chromatin Structure Induced by the Radioprotective Aminothiol, WR1065. British
Journal of Cancer, 60:893-896, 1989.
63.
Rotmensch, J., J.L. Schwartz, R.W. Atcher, D.J. Grdina, M. Toohill and R.R. Weichselbaum. The
Inherent Radiosensitivity of Epithelial Ovarian Carcinoma. Gynecology Oncology, 35:282-285,
1989.
64.
Rotmensch, J., J.L. Schwartz, M.A. Beckett, D.J. Grdina, M.F.P. Toohill, and R.R. Weichselbaum.
Characterization of a Human Ovarian Carcinoma. Analytical and Quantitative Cytology and
Histology, 11:324-330, 1989
65.
Van Beek, M.E.A.B., R.L. Doak, C.P. Sigdestad, and D.J. Grdina. Pathological Effects of the
Radiation Protector WR151327 in Mice. Radiation Research, 124:79-84, 1990.
66.
Gordon, D.J., A.E. Milner, R.P. Beaney, D.J. Grdina, and A.T.M. Vaughan. The Increase in
Radioresistance of Chinese Hamster Cells Cultured as Spheroids is Correlated to Changes in Nuclear
Morphology. Radiation Research, 121:175-179, 1990.
13
67.
Curriculum Vitae
David J. Grdina
Gordon, D.J., A.E. Milner, R.P. Beaney, D.J. Grdina, and A.T.M. Vaughan. Cellular
Radiosensitivity in V79 Cells is Linked to Alterations in Chromatin Structure. International Journal
of Radiation Oncology, Biology, Physics, 19:1199-1201, 1990.
68.
Meechan, P.J., A. Vaughan, D.J. Grdina. WR1065 Association With CHO AA8 Cells, Nuclei, and
Nucleoids. Radiation Research, 125: 152-157, 1991.
69.
Quiet, C.A., R.R. Weichselbaum, and D.J. Grdina. Variation in Radiation Sensitivity During the
Cell Cycle of Two Human Squamous Cell Carcinomas. International Journal of Radiation
Oncology, Biology, Physics, 20:733-738, 1991.
70.
Sigdestad, C.P., B. Bergquist, and D.J. Grdina. The Effect of Chemical Protectors on Cell Cycle
Progression After Gamma or Neutron Irradiation. Cell Proliferation, 24:271-280, 1991.
71.
Grdina, D.J., B.J. Wright, and B.A. Carnes. Protection by WR-151327 Against Late Effects Damage
Induced by Fission-Spectrum Neutrons. Radiation Research, 128(S):124-127, 1991.
72.
Hanson, W.R., and D.J. Grdina. Radiation Protection of Mice From Neutron Injury by Misoprostol,
a PGE1 Analog, Protects Mice from Fission-Neutron Injury. Radiation Research, 128(S):12-17,
1991.
73.
Schwartz, J.L., R. Mustafi, M.A. Beckett, E.A. Czyzewski, E. Farhangi, D.J. Grdina, J. Rotmensch,
and R.R. Weichselbaum. Radiation-Induced DNA Double-Strand Frequencies in Human Squamous
Cell Carcinoma Cell Lines of Different Radiation Sensitivities. International Journal of Radiation
Biology, 59:1341-1352, 1991.
74.
Murley, J.S., D.J. Grdina, and P.J. Meechan. Accumulation of CHO Cells in G2 Phase Following
Exposure to WR-1065. Radiation Research, 126:223-228, 1991.
75.
Sigdestad, C.P., A.M. Connor, D.J. Grdina, K.W. Doak. Chemical Radiation Protection from
Fission Spectrum Neutrons. Nuclear Science Applications, 4:157-166, 1991.
76.
Grdina, D.J., B.A. Carnes, D. Grahn, and C.P. Sigdestad. Protection Against Late Effects of
Radiation by S-2-(3-Aminopropylamino)-Ethylphosphorothioic Acid. Cancer Research, 51:41254130, 1991.
77.
Vaughan, A.T.M., D.J. Gordon, D. Grdina, and A.M. Milner. Analysis of Free Radical Damage
Within Single Cells Using Flow Cytometry. Molecular Aspects of Medicine, 12:129-135, 1991.
78.
Grdina, D.J., B.A. Carnes, and B. Nagy. Protection by WR2721 and WR151327 Against Late
Effects of Gamma Rays and Neutrons. Advances in Space Research, 12:(2)257-(2)263, 1992.
79.
Grdina, D.J., P. Dale, and R. Weichselbaum. Protection Against AZT-Induced Mutagenesis at the
HGPRT Locus in a Human Cell Line by WR-151326. International Journal of Radiation Oncology,
Biology, Physics, 22:813-815, 1992.
80.
Kataoka, Y., I. Basic, J. Perrin, and D.J. Grdina. Anti-Mutagenic Effects of Radioprotector WR2721 Against Fission-Spectrum Neutrons and 60Co -Rays in Mice. International Journal of
Radiation Biology, #3, 61:387-392, 1992.
14
Curriculum Vitae
David J. Grdina
81.
Meechan, P.J., D.J. Haraf, A.M. Diamond, and D.J. Grdina. Reversion of Radiosensitivity in
Azacytidine-Treated xrs-5 Cells Does Not Result in Full Radioprotection by WR-1065. International
Journal of Radiation Oncology, Biology, Physics, 23:999-1002, 1992.
82.
Grdina, D.J., and C.P. Sigdestad. Chemical Protection and Cell-Cycle Effects on Radiation-Induced
Mutagenesis. Cell Proliferation, 25:23-29, 1992.
83.
Rotmensch, J., R. Atcher, J. Schwartz, and D. Grdina. Analysis of Ascites from Patients with
Ovarian Carcinoma by Cell Flow Cytometry. Gynecological Oncology, 44:10-12, 1992.
84.
Carnes, B.A., and D.J. Grdina. In Vivo Protection by the Aminothiol WR-2721 Against NeutronInduced Carcinogenesis. International Journal of Radiation Biology, No. 5, 61:567-576, 1992.
85.
Grdina, D.J., Y. Kataoka, I. Basic, and J. Perrin. The Radioprotector WR-2721 Reduces NeutronInduced Mutations at the Hypoxanthine-Guanine Phosphoribosyl Transferase Locus in Mouse
Splenocytes When Administered Prior to or Following Irradiation. Carcinogenesis, vol. 13, no. 5,
pp. 811-814, 1992.
86.
Hallahan, D.E., S. Virudachalam, D. Grdina, and R.R. Weichselbaum. The Isoquinoline
Sulfonamide H7 Attenuates Radiation-Mediated Protein Kinase C Activation and Delays the Onset of
X-Ray Induced G2 Arrest. International Journal of Radiation Oncology, Biology, Physics, Vol 24,
687-692, 1992.
87.
Constantinou, A., D. Grdina, K. Kiguchi, and E. Huberman. The Effect of Topoisomerase inhibitors
on the Expression of Differentiation Markers and Cell Cycle Progression in Human K-562 Leukemia
Cells. Experimental Cell Research, 203: 100-106, 1992.
88.
Murley, J.S., D.J. Grdina, and P.J. Meechan. Effects of Growth Media on Cell Cycle Progression in
CHO Cells Exposed to the Radioprotector WR-1065. Cell Proliferation, 25: 643-650, 1992.
89.
Kataoka, Yasushi, Jane Perrin, and David J. Grdina. Induction of HPRT Mutations in Mice
following Exposure to Fission-Spectrum Neutrons or 60Co Rays. Radiation Research, 136:289-292,
1993.
90.
Grdina, D.J., A. Constantinou, N. Shigematsu, and J.S. Murley. Inhibition of Topoisomerase II
Activity in CHO K1 Cells by 2-[(Aminopropyl)Amino]Ethanethiol (WR-1065). Radiation Research,
138: 44-52, 1994.
91.
Grdina, D.J., and B.A. Carnes. Chemoprevention by WR-2721. Libri Oncologici 23:11-16, 1994.
92.
Hallahan, D.E., D. Bleakman, S. Virudachalam, D. Lee, D.J. Grdina, D. W. Kufe, and R.R.
Weichselbaum. The Role of Intracellular Calcium in the Cellular Response to Ionizing Radiation.
Radiation Research, 138: 392-400, 1994.
93.
Shigematsu, N., J.L. Schwartz, and D.J. Grdina. Protection Against Radiation-Induced Mutations at
the hprt locus by spermine and N,N -(dithiodi-2-1-Ethanediyl)bis-1,3-Propanediamine (WR-33278).
Mutagenesis 9:355-360, 1994.
15
94.
Curriculum Vitae
David J. Grdina
Matsushita, S., K. Ando, S. Koike, D.J. Grdina, and S. Furukawa. Radioprotection by WR-151327
Against the Late Normal Tissue Damage in Mouse Hind Legs from Gamma Ray Radiation.
International Journal of Radiation Oncology, Biology, and Physics, 30: 867-872, 1994.
95.
Schwartz, J.L., B.A. Sedita, N. Laffely, and D.J. Grdina. Chromosome Terminal Deletion Formation
in Chinese Hamster Ovary Cells. Mutation Research, 311: 125-131, 1994.
96.
Meechan, P.J., D.J. Haraf, A.M. Diamond, and D.J. Grdina. Varying Levels of Radioprotection
from the Effects of JANUS Neutrons in Repair Deficient XRS-5 Hamster Cells Treated with
AZAcytidine. Radiation Research, 140: 437-440, 1994.
97.
Thraves, P.J., S. Varghese, M. Jung, D.J. Grdina, J.S. Rhim, and A. Dritschilo. Transformation of
Human Epidermal Keratinocytes with Fission Neutrons. Carcinogenesis, 15: 2867-2873, 1994.
98.
Halpern, H.J., C. Yu, M. Peric, E. Barth, D.J. Grdina, B.A. Teicher. Oxymetry Deep in Tissues with
Low Frequency Electron Paramagnetic Resonance. Proceedings of the National Academy of
Sciences, USA, 91: 13047-13051, 1994.
99.
Grdina, D.J., N. Shigematsu, P. Dale, G.L. Newton, J.A. Aguilera, and R.C. Fahey. Thiol and
Disulfide Metabolites of the Radiation Protector and Potential Chemopreventive Agent WR-2721 are
Linked to Both its Anticytotoxic and Antimutagenic Mechanisms of Action, Carcinogenesis, 16:
767-774, 1995.
100.
Woloschak, G.E., T. Paunesku, C.R. Libertin, C.M. Chang-Liu, and D.J. Grdina. Expression of
Thymidine Kinase RNA and a Related Transcript is Modulated by Radioprotector WR-1065. Cancer
Research, 55:4788-4792, 1995.
101.
Murley, J.S. and D.J. Grdina. Effects of Cycloheximide and WR-1065 on Repair Processes Related
to Cell Survival and Mutagenesis Following Single and Split-doses of Radiation Exposure.
Carcinogenesis, 16:2699-2705, 1995.
102.
Halpern, H.J., G.V.R. Chandramouli, C. Yu, M. Peric, E.D. Barth, B.A. Teicher, and D.J. Grdina.
Pharmacological compartment viscosity and polarity measured with very low frequency EPR in
tumors of living animals. Magnetic Resonance in Chemistry, 33:S147-S153, 1995.
103.
Sidjanin, D., D.J. Grdina, and G.E. Woloschak. UV-Induced Changes in Cell Cycle and Gene
Expression within Rabbit Lens Epithelial Cells. Photochemistry and Photobiology, 63:79-85, 1996.
104.
Halpern, H.J., C. Yu, M. Peric, E.D. Barth, G.S. Karczamar, J.N. River, D.J. Grdina, and B.A.
Teicher. Measurement of Differences in pO2 Response to Perfluorocarbon/ Carbogen in FSa and
NFSa Murine Fibrosarcomas with Low Frequency Electron Paramagnetic Oxymetry. Radiation
Research, 145:610-618, 1996.
105.
Kataoka, Y., J. Perrin, N. Hunter, L. Milas and D.J. Grdina. WR-2721 Protects Against CytoxanInduced HPRT Mutagenesis Without Affecting Therapeutic Effectiveness. Seminars in Oncology,
23: Suppl. 8, 53-57, 1996.
106.
Diamond, A.M., J.L. Murray, P. Dale, R. Tritz, P.A. Sandstrom, and D.J. Grdina. The effects of
16
Curriculum Vitae
David J. Grdina
Selenium on Glutathione Peroxidase Activity and Radioprotection in Mammalian Cells. Radiat.
Onco. Investigations, 3: 383-386, 1996.
107.
Diamond, A.M., P. Dale, J.L. Murray, and D.J. Grdina. The inhibition of Radiation-Induced
Mutagenesis by the Combined Effects of Selenium and the Aminothiol WR-1065. Mutation
Research, 356:147-154, 1996.
108.
Schwartz, J.L., J. Cowan, D.J. Grdina, and R.R. Weichselbaum. Attenuation of G2 Cell Cycle
Checkpoint Control is Associated with Increased Frequencies of Unrejoined Chromosome Breaks in
Human Tumor Cell. Radiation Research, 146:139-143,1996.
109.
Woloschak, G.E., T. Paunesku, C.R. Libertin, C-M. Chang-Liu, M. Churchill, J. Panozzo, D. J.
Grdina, M.A. Gemmell, and C. Giometti. Regulation of Thymus PCNA Expression is Altered in
Radiation-Sensitive Wasted Mice. Carcinogenesis, 17:2357-2365, 1996.
110.
Liu, S.C., J.S. Murley, G. Woloschak, and D.J. Grdina. Repression of c-myc Gene Expression by
Thiol and Disulfide Forms of the Cytoprotector Amifostine. Carcinogenesis, 18:2457-2459,1997.
111.
Murley, J.S., A. Constantinou, N.S. Kamath, and D.J. Grdina. WR-1065, an Active Metabolite of
the Cytoprotector Amifostine, Affects Phosphorylation of Topoisomerase II Leading to Changes in
Enzyme Activity and Cell cycle progression in CHO AA8 Cells. Cell Proliferation,30:283-294,
1997.
112.
Grdina, D.J., J.S. Murley, and J.C. Roberts. Effect of Thiols on Topoisomerase-II Activity and
Cell Cycle Proliferation. Cell. Proliferation, 31: 217-229, 1998.
113.
Grdina, D.J., N. Hunter, Y. Kataoka, J. Murley, and L. Milas. Chemopreventive Doses of
Amifostine Confer No Cytoprotection to Tumor Nodules Growing in the Lungs of Mice Treated
with
Cyclophosphamide. Seminars in Oncology, 26 (#2 Suppl. F): 22-27, 1999.
114.
Kataoka, Y., A.M. Diamond, R.R. Weichselbaum, D.J. Grdina, and D.B. Mansur. Modification
of Anti-Oxidant Enzymatic Activity by Low Dose Selenium Supplementation Does Not Affect
Radiosensitivity of Human Malignant Glioma Cells. Libri Oncologici, 27:63-67, 1998.
115.
Cai, Y., M. Wu, S.M. Ludeman, D.J. Grdina, and E. Dolan. Role of O6-Alkylguanine-DNA
Alkyltransferase in Protecting against Cyclophosphamide-induced Toxicity and Mutagenicity
Cancer Res., 59:3059-3063, 1999.
116.
Kataoka, Y., J.S. Murley, R. Patel, and D.J. Grdina. Cytoprotection by WR-1065, the active form of
amifostine, is independent of p53 status in human malignant glioma cell lines. International Journal
of Radiation Biology, 76:633-639, 2000.
117.
Grdina, D.J., J.S. Murley, Y. Kataoka, and W. Epperly. Relationships between cytoprotection and
mutation prevention by WR-1065. Military Medicine, 167(2 Suppl):51-53, 2002.
118.
Snyder, R.D. and D.J. Grdina, Further evidence that the radioprotective aminothiol WR-1065
catalytically inactivates mammalian topoisomerase II. Cancer Res., 60:1186-1188, 2000.
17
119.
Curriculum Vitae
David J. Grdina
Mansur, D.B., Y. Kataoka, D.J. Grdina, and A. Diamond. Radiosensitivity of mammalian cell lines
engineered to over-express cytosolic glutathione peroxidase. Radiation Res., 155 (No 4):536-542,
2001.
120.
Murley, J.S., Y. Kataoka, D.E. Hallahan, J.C. Roberts, and D.J. Grdina. Activation of NFkB and
MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free
Radical Biology and Medicine, 30(No 12):1426-1439, 2001.
121.
Grdina, D.J., Y. Kataoka, J.S. Murley, N. Hunter, R.R. Weichselbaum, and L. Milas. Inhibition of
spontaneous metastases formation by Amifostine. International Journal of Cancer, 97:135-141,
2002.
122.
Grdina, D.J., J.S. Murley, Y. Kataoka, and D.P. Calvin, Differential activation of nuclear
transcription factor kB, gene expression, and proteins by Amifostine’s free thiol in human
microvascular endothelial and glioma cells. Seminars in Radiation Oncology, 12(No. 1),Suppl.
1:103-111, 2002.
123.
Khodarev, N.N., J. Yu, E. Nodzenski, J.S. Murley, Y. Kataoka, C.K. Brown, D.J. Grdina, R.R.
Weichselbaum, Method of RNA purification from endothelial cells for DNA array experiments.
BioTechniques, 32:316-320, 2002.
124.
Kataoka, Y., J.S. Murley, N.N. Khodarev, R.R. Weichselbaum, and D.J. Grdina, Activation of the
nuclear transcription factor B (NFB) and differential gene expression in U87 glioma cells
following exposure to the cytoprotector amifostine. International Journal of Radiation Oncology,
Biology, Physics, 53:180-189, 2002.
125.
Murley J.S., Y. Kataoka, C.J. Weydert, L.W. Oberley, and D.J. Grdina, Delayed cytoprotection
following enhancement of MnSOD gene expression in SA-NH mouse sarcoma cells exposed to
Amifostine’s active metabolite WR1065. Radiation Research, 158:101-109, 2002.
126.
Grdina, D.J., , J.S. Murley, and Y. Kataoka, Radioprotectants: Current Status and New Directions.
Oncology, 63(suppl 2):2-10, 2002.
127.
Grdina, D.J., Y. Kataoka, J.S. Murley, K. Swedberg, J.Y. Lee, N. Hunter, R.R. Weichselbaum, and
L. Milas, Anti-metastatic effectiveness of amifostine therapy following surgical removal of Sa-NH
tumors in mice. Seminars in Oncology, 29, No. 6, (Suppl 18):22-28, 2002.
128.
Elas, M., A. Parasca, D.J. Grdina, H.J. Halpern: Oral administration is as effective as intraperitoneal
administration of amifostine in decreasing nitroxide EPR signal decay in vivo. Biochemica et
Biophysica Acta, 1637:151-155, 2003.
129.
Khodarev, N.N., Y. Kataoka, J.S. Murley, R.R. Weichselbaum, and D.J. Grdina: Interaction of
amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human
microvascular endothelial cells (HMEC). Int. J. Radiat. Oncol., Biol., Phys. 60(2):553-563, 2004.
130.
J.S, Murley, Y. Kataoka, and D.J. Grdina: Delayed radioprotection via NFkB mediated induction of
Sod2 (MnSOD) in SA-NH tumor cells following exposure to clinically used thiol containing drugs.
Radiat. Res. 162 (5):536-546, 2004.
18
131.
Curriculum Vitae
David J. Grdina
Stone H.B., J.E. Moulder, C.N. Coleman, K.K. Ang, M.S. Anscher, M.H. Barcellos-Hoff, W.S.
Dyan, J.R. Fike, D.J. Grdina, et al., Models for evaluating agents intended for the prophylaxis,
mitigation and treatment of radiation injuries. Radiat. Res. 162(6):711-728, 2004.
132.
Grdina, D.J., J.S. Murley, Y. Kataoka, D. Zhou, and T.M. Seed: Radioprotectors: Current Status and
New Directions, Radiat. Res. 163(6):704-705, 2005.
133.
Murley, J.S., Y. Kataoka, C.J. Weydert, L.W. Oberley, and D.J. Grdina, Delayed radioprotection by
nuclear transcription factor kB-mediated induction of Manganese Superoxide Dismutase in Human
Microvascular Endothelial Cells after exposure to free radical scavenger WR1065, Free Radical
Biol. Med., 40:1004-1016, 2006.
134.
Kataoka, Y., V.P. Bindokas, R.C. Duggan, J.S. Murley, and D.J. Grdina. Flow cytometric analysis
of phosphorylated histone H2AX following exposure to ionizing radiation in human microvascular
endothelial cells, J. Radiat. Res. 47(3-4):245-257, 2006.
135.
Murley, J.S., Y. Kataoka, K.L. Baker, A. Diamond, W.F. Morgan, and D.J. Grdina. Manganese
Superoxide Dismutase (Sod2) Mediated Delayed Radioprotection Induced by the Free Thiol Form of
Amifostine and Tumor Necrosis Factor-α, Radiat. Res. 167:465-474, 2007.
136.
Kataoka, Y., J.S. Murley, K. Baker, and D.J. Grdina. Relationship Between Phosphorylated Histone
H2AX Formation and Cell Survival in Human Microvascular Endothelial Cells (HMEC) as a
Function of Ionizing Radiation Exposure in the Presence or Absence of Thiol Containing Drugs.,
Radiat. Res., 168:106-114, 2007.
137.
Murley, J.S., D. Nantajit, K.L. Baker, Y. Kataoka, J.J. Li, and D.J. Grdina. Maintenance of
Manganese Superoxide Dismutase (Sod2)-Mediated Delayed Radioprotection Induced by Repeated
Administration of the Free Thiol Form of Amifostine. Radiat. Res., 169:495-505, 2008.
138.
Paunesku D., T. Paunesku, A. Wahl, Y. Kataoka, J. Murley, D.J. Grdina, G.E. Woloschak. Incidence
of Tissue Toxicities in Gamma Ray and Fission Neutron-Exposed Mice Treated with Amifostine.
Int. J. Radiat. Biol., 84(8):623-634, 2008.
139.
Dziegielewski J., J.E. Baulch, W. Goetz, M.C. Coleman, D.R. Spitz, J.S. Murley, D.J. Grdina, W.F.
Morgan. WR1065, the Active Metabolite of Amifostine, Mitigates Radiation-Induced Delayed
Genomic Instability. Free Radical Biol. Med., 45(12):1674-1681, 2008.
140.
Grdina D.J., J.S. Murley, Y. Kataoka, K.L. Baker, R. Kunnavakkam, M.C. Coleman, and D.R. Spitz.
Amifostine Induces Anti-Oxidant Enzymatic Activities in Normal Tissues and a Transplantable
Tumor That Can Affect Radiation Response. Int. J. Rad. Oncol. Biol. Phys.,73(3):886-896, 2009.
141.
Fu P., A.A. Birukova, J. Xing, S. Sammani, J.S. Murley, J.G. Garcia, D.J. Grdina, K.G. Birukov.
Amifostine reduces lung vascular permeability via suppression of inflammatory signaling. Eur.
Respir. J., 33(3):612-624, 2009.
142.
Ahmed, K.M., D. Nantajit, M. Fan, J.S. Murley, D.J. Grdina, Li, J.J. Co-activation of
ATM/ERK/NF-κB in Low Dose Radiation-Induced Adaptive Radioresistance in Human Skin
Keratinocytes. Free Radical Biol. Med., 46(11):1543-1550, 2009.
19
143.
Curriculum Vitae
David J. Grdina
Hooker, A.M., D.J. Grdina, J.S. Murley, B.J. Blyth, R.J. Ormsby, E. Bezak, K.A. Giam, P.M. Sykes.
Low doses of amifostine protect from chromosomal inversions in spleen in vivo when administered
after an occupationally relevant X-radiation dose. Int. J. Low Radiat., 6(1):43-56, 2009.
144.
Dziegielewski, J., W. Goetz, J.S. Murley, D.J. Grdina, W.F. Morgan, and J.E. Baulch. Amifostine
metabolite WR-1065 disrupts homologous recombination in mammalian cells. Radiat. Res.,173:175183, 2010.
145.
Murley, J.S., Y. Kataoka, R.C. Miller, J.J. Li, G. Woloschak, D.J. Grdina. SOD2-mediated effects
induced by WR1065 and low-dose ionizing radiation on micronucleus formation in RKO human
colon carcinoma cells. Radiat. Res. 175: 57-65, 2011.
146.
Fu, P., J.S. Murley, D.J. Grdina, A.A. Birukova, K.G. Birukov. Induction of cellular antioxidant
defense by amifostine improves ventilator-induced lung injury. Crit. Care Med. 39(12):2711-2721,
2011.
147.
Murley, J.S., K.L. Baker, R.C. Miller, T.E. Darga, R.R. Weichselbaum, D.J. Grdina. SOD2mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and
amifostine. Free Radical Biol. Med. 51: 1918-1925, 2011.
II.
PEER REVIEWED CHAPTERS
148.
Grdina, D.J. Separation of Clonogenic Cells from Stationary Phase Cultures and a Murine
Fibrosarcoma by Density Gradient Centrifugation. In Methods in Cell Biology, Vol. 14, Chapter 20.
D.M. Precott, ed. New York, New York: Academic Press, Inc., 1976, pp. 213-228.
149.
Meistrich, M.L., D.J. Grdina, and R.E. Meyn. Application of Cell Separation Methods to the Study
of Cell Kinetics and Proliferation. In Growth Kinetics and Biochemical Regulation of Normal and
Malignant Cells. B. Drewinko and R.M. Humphrey, eds., pp. 131-142, Williams and Wilkins,
Baltimore, Maryland, 1977.
150.
Grdina, D.J. Variations in Radiation Response of Tumor Subpopulations. In: Radiation Biology in
Cancer Research. R.E. Meyn and H.R. Withers, eds., Raven Press, pp. 353-363, New York, 1980.
151.
Meyn, R.E., D.J. Grdina, and S.E. Fletcher. Repair of Radiation Damage in vivo. In: Radiation
Biology in Cancer Research. R.E. Meyn and H.R. Withers, eds., Raven Press, New York, pp. 95102, 1980.
152.
Grdina, D.J., and M.L. Meistrich. Separation of Solid Tumor Cell Populations. In Antibiotics and
Chemotherapy, Design and Cancer Chemotherapy, Vol. 28. E. Mihich and S. Eckhardt, eds., Vol,
28, pp. 137-141, Basel: S. Karger AG Medical Publishers, 1980.
153.
Grdina, D.J. Radiation Biology of Tumor Subpopulations. In Radiation Biology, Vol. VI, within the
CRC Uniscience Series: Radiotracers in Biology and Medicine. D.J. Pizzarello, ed., pp. 129-148,
CRC Press, New York, 1982.
20
154.
Curriculum Vitae
David J. Grdina
Grdina, D.J., M.L. Meistrich, R.E. Meyn, T.S. Johnson, and R.A. White. Cell Synchrony
Techniques, A Comparison of Methods. In Techniques in Cell Cycle Analysis, Chapter 12. J.E. Gray
and Z. Darzynkiewicz, eds. Clifton, New Jersey: The Humana Press, Inc., 1986, pp. 367-402.
155.
Grdina, D.J. and C.P. Sigdestad. Radiation Protectors: The Unexpected Benefits. Drug Metabolism
Reviews, 20:13-42, 1989.
156.
Vaughan, A.T.M., D.J. Gordon, D.J. Grdina, and A.E. Milner. Analysis of Radiation and Chemical
Damage in Mammalian Cells. In Flow Cytometry: A Practical Approach, M.G. Ormerod, ed. IRL
Press, Oxford. Chap. 10, pp. 229-240, 1990.
157.
Grdina, D.J., B. Nagy, and P.J. Meechan. Effect of an Aminothiol (WR1065) on Radiation-Induced
Mutagenesis and Cytotoxicity in Two Repair-deficient Mammalian Cell Lines. In
Anticarcinogenesis and Radiation Protection: Strategies in Protection from Radiation and Cancer,
O. Nygaard, ed., pp. 287-295, Plenum Publishing Corp. New York, 1991.
158.
Nagy, B., D.J. Grdina, and C.R. Ashman. JANUS Neutron Irradiation of a Mouse Cell Line
Containing a Shuttle Vector Plasmid. In Anticarcinogenesis and Radiation Protection: Strategies in
Protection from Radiation and Cancer, O. Nygaard, ed., pp. 85-92, Plenum Publishing Corporation,
New York, 1991.
159.
Basic, I., D.J. Grdina, and T. Lyons. Application of an In Vivo Mutagenesis System to Assess
Aminothiol Effects on Neutron-induced Genotoxic Damage in Mouse Splenocytes. In
Anticarcinogenesis and Radiation Protection: Strategies in Protection from Radiation and Cancer,
O. Nygaard, ed. Plenum Publishing Corporation, New York, New York, pp. 297-301, 1991.
160.
Murley, J.S. and D.J. Grdina. Chemoprevention with WR-2721 and its Metabolites. In:
Radioprotectors, CRC Press, E. Bump and K Malaker eds., New York, New York, pp. 299313, 1998.
161.
Grdina, D.J, Y. Kataoka, and J.S. Murley. Amifostine: Mechanisms of Action Underlying
Cytoprotection and Chemoprevention. Drug Metabolism and Drug Interactions, 16 (No. 4):1-43,
2002.
162.
Little, J.B., D.J. Grdina. Ionizing Radiation, In: Cancer 7 Medicine, Chapter 16, Holland-Frei Eds.,
B.C. Decker Inc., Hamilton, Ontario, CA, pp. 270-282, 2006.
163.
Grdina, D.J., Ionizing Radiation, In: Cancer 8 Medicine, Chapter 16, Holland-Frei Eds., B.C. Decker
Inc., Hamilton, Ontario, CA. 2009.
164.
Murley, J.S., Y. Kataoka, D.J. Grdina. Amifostine and the Endogenous Cellular Antioxidant Enzyme
Manganese Superoxide Dismutase in Radioprotection. In: Oxidative Stress in Clinical Practice,
Humana Press/Springer Science. Pp. 149-168, 2011.
III.
MISCELLANEOUS
165.
Grdina, D.J. Physiologically-Induced Changes in the Repair of Gamma-Ray-Induced Single-Strand
Breaks in Escherichia coli K-12. Ph.D. Thesis, University of Kansas, Lawrence, Kansas, 1971.
21
166.
Curriculum Vitae
David J. Grdina
Basic, I., L. Milas, D.J. Grdina, and H.R. Withers. In vitro Destruction of Tumor Cells by Murine
Macrophages Stimulated with Corynebacterium granulosum. Periodicum Biologorum, 78:134-136,
1976. (Proceedings of the Yugoslav Immunological Society.)
167.
Grdina, D.J. Research Sheds Light on Chemicals that Protect Against Radiation, Logos, 4:2-5, 1986.
168.
Grdina, D.J. Molecular Mechanisms in Cytoprotection and Chemoprevention with ETHYOL
(amifostine). Pro ED COMMUNICATIONS, INC. Pub., Beachwood, Ohio, 1997.
INVITED LECTURES:
1.
Radiation sensitivity of tumor cell populations separated from a fibrosarcoma by density gradient
centrifugation. Duke University, North Carolina, September 16, 1974.
2.
Comparative studies of the radiation sensitivity of tumor cell populations separated from a solid
tumor. Medical College of Wisconsin, Milwaukee, Wisconsin, October 21, 1974.
3.
Separation of hypoxic cells from a solid tumor. University of Wisconsin, Madison, Wisconsin,
December 29, 1975.
4.
Tumor radiobiology: A study of the cellular parameters of density, size, and DNA content as related
to clonogenicity and radiation response. University of Utah, Salt Lake City, Utah, June 8, 1977.
5.
Formation of lung metastases: An analysis based on cellular parameters of density, size, and DNA
content. University of Kansas, Lawrence, Kansas, June 30, 1977.
6.
The use of cell separation procedures to study the relationship(s) between density, size, and DNA
content of tumor cells and the parameters of clonogenicity and radiation sensitivity. New Mexico
School of Medicine, Albuquerque, New Mexico, August 8, 1977.
7.
Tumor cell separation techniques in experimental chemotherapy and radiotherapy. University of
Louisville, Louisville, Kentucky, December 12, 1978.
8.
Tumor cell separation techniques in experimental chemotherapy and radiotherapy. Argonne National
Laboratory, Argonne, Illinois, August 22, 1979.
9.
Variations in radiation response of tumor subpopulations. The 32nd Annual Symposium on
Fundamental Cancer Research, The University of Texas System Cancer Center, M.D. Anderson
Hospital and Tumor Institute, Houston, Texas, February 28, 1979.
10.
Variations in the radiation response of tumor subpopulations. Rush-Presbyterian-St. Luke's Medical
Center, Chicago, Illinois, June 23, 1980.
11.
Tumor heterogeneity and radiation biology. Section of Experimental Radiation Oncology, U.C.L.A.,
Los Angeles, California, March 2, 1980.
12.
Workshop on: Cell separation and tumor cell kinetics. VIII Conference on Analytical Cytology and
Cytometry, Portsmouth, New Hampshire, May 21, 1981.
22
13.
Curriculum Vitae
David J. Grdina
Tumor cell separation techniques in experimental chemotherapy and radiotherapy. 1981-1982
Oncology Lecture Series, University of Louisville Cancer Center, Louisville, Kentucky, November
16, 1981.
14.
Comparison of synchrony techniques, invited workshop participant. Cell Kinetics Society, Houston,
Texas, March 21, 1982.
15.
Tumor cell heterogeneity. Radiation Research Society, Symposium invited speaker, Salt Lake City,
Utah, April 21, 1982.
16.
Tumor cell heterogeneity. Argonne National Laboratory, Argonne, Illinois, March 15, 1983.
17.
Cell separation approaches to tumor heterogeneity. University of Kansas, Lawrence, Kansas,
September 30, 1983.
18.
Tumor heterogeneity and radiation biology: A search for prognostic indicators of tumor response.
Johns Hopkins Oncology Center, Baltimore, Maryland, October 25, 1983.
19.
Application of cell separation techniques to experimental chemotherapy and radiotherapy. Johns
Hopkins Oncology Center, Baltimore, Maryland, October 26, 1983.
20.
Tumor heterogeneity and radiation biology: A search for prognostic indicators of tumor response.
Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, November 9, 1983.
21.
Effects of radioprotectors on cell killing, mutagenesis, and transformation. Dept. of Exp.
Radiotherapy, M.D. Anderson Hospital and Tumor Institute, Houston, Texas, June 27, 1984.
22.
Tumor heterogeneity and radiation biology: Department of Biological Sciences, Institute of
Technology, Chicago, IL, September 10, 1984.
23.
Tumor heterogeneity and radiation biology. A search for prognostic indicators of tumor response.
Department of Biology, Northern Illinois University, DeKalb, IL, November 1, 1984.
24.
Radiation protectors as anticarcinogens. Cleveland Clinic, Dept. of Radiation Biology, Cleveland,
Ohio, October 8, 1985.
25.
Effects of radiation. Workshop on Recombinant DNA for Beginners, Argonne National Laboratory,
Argonne, IL, July 28, 1986.
26.
Cancer prevention: Application of chemicals in treatment therapy to reduce risk in secondary tumor
induction. Opportunities in the Oncology Marketplace, The Drake Hotel, Chicago, IL, October 15,
1986.
27.
The application of radioprotector compounds to reduce the risk of radiation-induced mutagenesis and
carcinogenesis. CSUI-ANL Conference, Collaborative Research at DOE National Laboratories,
Argonne National Laboratory, Argonne, IL, October 30, 1986.
28.
Application of chemicals in treatment therapy to reduce risk in secondary tumor induction.
University of Pennsylvania, Department of Radiation Oncology, November 10, 1986.
23
29.
Curriculum Vitae
David J. Grdina
Tumor heterogeneity and radiation biology. University of Pennsylvania, Department of Radiation
Oncology, January 9, 1987.
30.
Radiation damage and protection. Division of Educational Programs, Argonne National Laboratory,
Argonne, Illinois, February 27, 1987.
31.
Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Perspectives in
Radioprotection, AFRRI, Bethesda, Maryland, March 13, 1987.
32.
Role of radioprotectors in DNA damage and repair, damage to protein, and effects on cell
progression. Perspectives in Radioprotection, AFRRI, Bethesda, Maryland, March 13, 1987.
33.
Tumor heterogeneity and radiation biology. Loyola University Medical Center, Maywood, Illinois,
March 20, 1987.
34.
Effects of aminothiols on DNA damage, mutagenesis and carcinogenesis. Lawrence Berkeley
Laboratory, Berkeley, California, October 5, 1987.
35.
The application of radiation protectors in treatment therapy to reduce risk in secondary tumor
induction. University of California at San Francisco, California, October 6, 1987.
36.
Effects of aminothiols on DNA damage, repair, mutagenesis and carcinogenesis. National Bureau of
Standards, Gaithersburg, Maryland, October 16, 1987.
37.
The antimutagenic and anticarcinogenic effects of selected free radical scavenging aminothiols. 1987
ISSX/SOT Clearwater Symposium, Clearwater, Florida, November 11, 1987.
38.
The effects of WR1065 and WR151326 on cell-cycle progression. The Division of Clinical Research
in the National Institute of Radiological Sciences (NIRS), Chiba-chi, Japan, Feb. 1, 1988.
39.
Neutron DNA damage and repair and their modulation by aminothiols. Tokyo Metropolitan Institute
of Medical Science, Tokyo, Japan, Feb. 2, 1988.
40.
Effect of aminothiols on neutron and gamma-ray-induced DNA damage and repair. NIRS, Chibachi, Japan, Feb. 3, 1988.
41.
The application of aminothiols as antimutagenic and anticarcinogenic agents in cancer treatment for
the prevention of therapy-induced secondary tumors. Faculty of Medicine, Kyushu University,
Fukuoka, Japan, Feb. 9, 1988.
42.
The effect of aminothiols on DNA damage and repair as a function of radiation quality. Radiation
Biophysics Department, Nagasaki University, Nagasaki, Japan, Feb. 10, 1988.
43.
The effect of radiation quality and the presence of aminothiols on DNA damage and repair.
Radiation Effects Research Foundation, Hiroshima, Japan, Feb. 15, 1988.
44.
The application of aminothiols to reduce risk of secondary tumors due to radiation and/or
chemotherapy. NIRS, Chiba-chi, Japan, Feb. 22, 1988.
24
45.
Curriculum Vitae
David J. Grdina
Use of aminothiols to protect against secondary tumor induction as a result of treatment therapy; and
effect of aminothiols on neutron- and gamma-ray-induced DNA damage and repair. Dept. of
Radiation Oncology, University of Tokyo, Tokyo, Japan, Feb. 23, 1988.
46.
Antimutagenic and anticarcinogenic properties of WR2721: Application to the clinic. Dept. of
Experimental Radiotherapy, M.D. Anderson Hospital and Tumor Institute, Houston, Texas, Dec. 6,
1988.
47.
Antimutagenic and anticarcinogenic properties of aminothiols: Applications to the clinic and the
workplace. Dept. of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania,
Feb. 2, 1989.
48.
Aminothiol mediated antimutagenesis and anticarcinogenesis. Biology Division, Argonne National
Laboratory, Argonne, Illinois, Feb. 9, 1989.
49.
Antimutagenic and anticarcinogenic effects of WR2721: Application to the clinic. Grand Rounds,
Dept. of Radiation Oncology, University of Wisconsin, Madison, Wisconsin, March 2, 1989.
50.
Antimutagenic and anticarcinogenic effects of aminothiols. Radiation Oncology Training Program
and Bioengineering Faculty, University of Illinois, Urbana, Illinois, Sept. 27, 1989.
51.
Antimutagenic and anticarcinogenic effects of aminothiols: Applications to the clinic and workplace.
Third International Conference on Anticarcinogenesis and Radiation Protection, Dubrovnik,
Yugoslavia, Oct. 20, 1989.
52.
Aminothiols as antimutagens and anticarcinogens. Rudjer Boskovic Institute, Zagreb, Yugoslavia,
Oct. 25, 1989.
53.
Antimutagenic and anticarcinogenic effects of WR2721 and WR151327. Developmental
Therapeutics Branch, Division of AIDS, National Cancer Institute, Rockville, Maryland, Dec. 13,
1989.
54.
Protection against therapy-induced secondary tumors. Chicago Radiological Society, Chicago,
Illinois, April 19, 1990.
55.
Protection by WR-2721 against late effects of radiation (gamma rays and neutrons). 28th Cospar
Meeting, The Hague, The Netherlands, June 27, 1990.
56.
Protection against therapy-induced secondary tumors. The Gray Laboratory, Mount Vernon
Hospital, Northwood, England, June 2, 1990.
57.
Protection against therapy-induced tumors. The Medical Research Council, Harwell, Didcot,
Oxfordshire, England, June 5, 1990.
58.
Use of repair defective mammalian cells and exogenous thiols to study mechanisms of radiation
resistance. NCI Radioresistance Workshop, Washington, D.C., Sept. 18, 1990.
59.
Protection by WR-151327 against late-effect damage induced by fission-spectrum neutrons. Armed
Forces Radiobiology Research Institute, International Colloquium on Neutron Radiation Biology,
Rockville, Maryland, Nov. 7, 1990.
25
Curriculum Vitae
David J. Grdina
60.
Antimutagenic and anticarcinogenic effects of WR-2721 and WR-151327. Monsanto Chemical Co.,
St. Louis, Missouri, Dec. 19, 1990.
61.
Antimutagenic and anticarcinogenic effects of radioprotective aminothiols. Marion Merrell Dow,
Cincinnati, Ohio, Jan. 24, 1991.
62.
Role of aminothiols in protection against carcinogenesis and mutagenesis. Armed Forces
Radiobiology Research Institute, Bethesda, Maryland, Feb. 20, 1991.
63.
Role of aminothiols in carcinogenesis and mutagenesis. Dept. of Experimental Radiotherapy, M. D.
Anderson Hospital and Tumor Institute, University of Texas Health Science Center, Houston, Texas,
Nov. 18, 1991.
64.
Chemoprevention by aminothiols in radiation and chemotherapy. University of Chicago, Chicago,
Illinois, Jan. 30, 1992.
65.
Cell survival, mutagenesis, and aminothiols. 40th Annual Meeting of the Radiation Research
Society, invited Symposium Speaker, Salt Lake City, Utah, March 18, 1992.
66.
Can we provide methods of reducing the risk of cancer and genetic effects? Workshop #2 supporting
NASA design study for manned mission to Mars, Armed Forces Radiobiology Research Institute,
Bethesda, Maryland, Sept. 22, 1992
67.
Use of WR-2721 in chemoprevention. Dept. of Microbiology and Molecular Genetics, University of
Vermont, Burlington, Vermont, Feb. 3, 1993.
68.
Chemo Prevention by WR-2721 and WR-151327. Second International Cancer Chemo Prevention
Conference, Berlin, Germany, April 29, 1993.
69.
Role of WR-2721 in DNA damage and repair. Basic Science Advisory Committee presentation, U.S.
Bioscience, West Conshohocken, Pennsylvania, July 15, 1993.
70.
Antimutagenic effects of WR-2721 following alkylating agent therapy. Cancer and Leukemia Group
B, Clinical Trials, Oak Brook, Illinois, Nov. 3, 1993.
71.
Chemoprevention by aminothiols in radiation and chemotherapy. 1st Annual John Yuhas Memorial
Lecture, University of Pennsylvania, Philadelphia, Pennsylvania, Nov. 10, 1993.
72.
Chemoprevention by aminothiols in radiation and chemotherapy. Northern Illinois University, De
Kalb, Illinois, Jan. 21, 1994.
73.
Antimutagenic and anticarcinogenic effects of WR151327. U.S. Bioscience and the Department of
Energy, Washington, DC, August 9, 1994.
74.
Chemoprevention by Aminothiols: Biochemical and Molecular Mechanisms. Center for
Mechanistic Biology and Biotechnology, Argonne National Laboratory, Argonne, Illinois, November
17, 1994.
26
75.
Curriculum Vitae
David J. Grdina
Chemoprevention by Aminothiols. Invited Symposium Talk, 43rd Radiation Research Society
Meeting, San Jose, California, April 5, 1995.
76.
Chemoprevention by Aminothiols: Molecular Mechanisms. Department of Medicine, University of
Chicago, Chicago, Illinois, April 17, 1995.
77.
WR-2721 Protects Against Cytoxan-Induced Mutagenesis at the HPRT Locus without Affecting
Therapeutic Effectiveness. Christ Church College, Oxford, United Kingdom, August 23, 1995.
78.
Chemoprevention by Amifostine. ECCO-8, Schering Plough, Paris, France, October 30, 1995.
79.
Antimutagenicity Effects of Amifostine: Clinical Implications. University of Arizona Cancer Center
Workshop, West Palm Beach, Florida, December 8, 1995.
80.
Molecular Mechanisms Underlying the Chemoprotective and -Preventive Properties of Amifostine.
Satellite Symposium "Cytoprotection with Amifostine in Tumor Therapy", 22nd German Cancer
Congress, Berlin, Germany, February 20, 1996.
81.
Aminothiols in Chemoprevention: Molecular Mechanisms of Action. Invited Symposium Talk, 44th
Radiation Research Society Meeting, Chicago, Illinois, April 14, 1996.
82.
Cytoprotection Educational Forum: Mutagenesis. The Warwick Hotel, Philadelphia, Pennsylvania,
May 17, 1996.
83.
Molecular Mechanisms of Ethyol in Cytoprotection and Chemoprevention. Recent Advances in
Research and Practice in Cytoprotection. Frankfurt, Germany, June 8, 1996.
84.
Protection Against Cancer-Therapy Induced Toxicities. Department of Hematology and Oncology,
St. Lukes Hospital, New York, New York, June 27, 1996.
85.
Protection Against Radiation Induced Mutagenesis and Carcinogenesis by Amifostine and
WR151327. D.O.E. Conference on: Use of the Radioprotector Ethyol (Amifostine) for Planned
Radiation Exposures During Emergencies, Bethesda, MD, August 15-16, 1996.
86.
Molecular Mechanisms of Ethyol in Cytoprotection and Chemoprevention. New Mexico Society of
Clinical Oncology Annual Meeting, Doubletree Hotel, Albuquerque, New Mexico, October 18, 1996.
87.
Aminothiols With and Without Radiation Therapy in the Management of Solid Cancers. Southwest
Oncology Group Fall Meeting, Gynecologic Cancer Basic Science Subcommittee, Chicago, Illinois,
October 19, 1996.
88.
Role of Amifostine in Cytoprotection and Chemoprevention: Molecular Mechanisms, University of
Illinois at Chicago Cancer Center, Chicago, Illinois, February 24, 1997.
89.
Protection Against Cancer-Therapy Induced Toxicities, Northern California Kaiser Oncology
Pharmacists Quarterly Meeting, Oakland, California, March 11, 1997.
90.
Molecular Mechanisms Underlying the Cytoprotective and Chemopreventive Properties of Ethyol,
EORTC Head and Neck Cancer Coorperative Group Meeting, Brussels, Belgium, March 14, 1997.
27
91.
Curriculum Vitae
David J. Grdina
Cytoprotection and Cell Cycle, University of Chicago, Dept. Of Radiation and Cellular Oncology,
Chicago Illinois, April 15, 1997.
92.
Mechanisms Underlying the Cytoprotective and Chemopreventive Properties of Ethyol, Past and
Present Role of Ethyol in Cancer Therapy, Ethyol Advisory Board Meeting, Los Angeles, California,
May 10, 1997.
93.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol, University of Illinois College of
Medicine, Department of Pharmacology, Chicago, Illinois, May 22, 1997.
94.
Mechanisms Underlying the Cytoprotective and Chemopreventive Properties of Ethyol, Past and
Present Role of Ethyol in Cancer Therapy, Ethyol Advisory Board Meeting, Tucson, Arizona, May
31, 1997.
95.
Molecular Mechanisms Underlying the Cytoprotective and Chemopreventive Properties of Ethyol,
Cox Health Care Systems, Springfield, Missouri, June 20, 1997.
96.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol, University of Washington,
Department of Radiation Oncology, Seattle, Washington, January 15, 1998.
97.
Mechanisms in Cytoprotection and Chemoprevention of Ethyol in Radiation Oncology, Ethyol
Advisory Meeting, Tucson, Arizona, March 21, 1998.
98.
Mechanisms in Cytoprotection and Chemoprevention of Ethyol in Radiation Oncology, Ethyol
Advisory Meeting, Los Angeles, California, May 16, 1998.
99.
Mechanisms in Cytoprotection and Chemoprevention of Ethyol in Radiation Oncology,
University of Texas M.D. Anderson Cancer Center, Houston, Texas, August 11, 1998.
100.
The Use of Radiation and Radionuclides in Animal Research- Basics of Radioactivity,
American Association for Laboratory Animal Science, 49th National Meeting,
Cincinnati, Ohio, October 20, 1998.
101.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol, Northwestern University,
Chicago, Illinois, December 17, 1998.
102.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol in Radiation Oncology,
Northwestern University, Department of Radiation Oncology, Chicago, Illinois, January 14, 1999.
103.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol in Radiation Oncology,
Rush Medical School, Department of Radiation Oncology, Chicago, Illinois, January 28, 1999.
104.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol in Radiation Oncology,
American College of Radiology, Southwest Meeting, Albuquerque, New Mexico,
February 13, 1999.
105.
Mechanisms of Cytoprotection and Chemoprevention by Ethyol in Radiation Oncology,
Geisinger Medical Center, Accredited through Penn. State University of Continuing
Education, Harrisburg, Pennsylvania, March 11, 1999.
28
106.
Curriculum Vitae
David J. Grdina
Underlying Mechanisms of Ethyol for Cytoprotection and Chemoprevention in Radiation
Oncology, Department of Radiation Oncology, University of Utah, Salt Lake City, Utah, March
31, 1999.
107.
Mechanisms of Cytoprotection and Chemoprevention by Amifostine (Ethyol) in Radiation
Biology,
Dutch Radiobiological Society, Haarlem, Netherlands, April 16, 1999.
108
Amifostine: Mechanism of Action, Presentation to ODAC at FDA Meeting, Silver Springs,
Maryland, June 8, 1999.
109.
Amifostine: Mechanisms of Action for Cytoprotection and Chemoprevention, Northern California
Health Care, Oakland, California, August 24, 1999.
110.
Amifostine: Mechanisms of Action for Cytoprotection and Chemoprevention, Sacramento Nurses,
Sacramento, California, August 25, 1999.
111.
Mechanisms of Cytoprotection and Chemoprevention by Amifostine, Williamsport, Pennsylvania,
October 13, 1999.
112.
Mechanisms of Cytoprotection and Chemoprevention by Amifostine, Binghampton, New York,
October 14, 1999.
113.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Symposium,
ASTRO, San Antonio, Texas, October 30, 1999.
114.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, International
Conference on Low-Level Radiation Injury and Medical Counter Measures, Bethesda, Maryland,
November 8, 1999.
115.
Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention, Bridgeport,
Connecticut, December 3, 1999.
116.
Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention, Cleveland
Clinic, Cleveland, Ohio, December 10, 1999.
117.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of
Radiation Oncology, University of Wisconsin, Madison, Wisconsin, January 18, 2000.
118.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of
Radiation Oncology, Georgetown University, Washiongton D.C., January 28, 2000.
119.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Physicians in South
Florida, Fort Meyers, Florida, March 18, 2000.
120.
Amifostine for Use in Cytoprotection and the Prevention of Therapy Induced Secondary Tumors,
Radiation Workshop at Round Top, M.D. Anderson Cancer Center, Round Top, Texas, April 15,
2000.
29
121.
Curriculum Vitae
David J. Grdina
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of
Radiation Oncology, University of Rochester, Rochester, New York, May 10, 2000.
122.
Amifostine: the molecular mechanisms of action and novel roles in cancer treatment. XVI EACR
Meeting, Chalkidiki, Greece, May 30, 2000.
123.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of
Radiation Oncology, New England Medical Center, Boston, Massachusetts, June 16, 2000.
124.
Mechansims of Action of Amifostine in Cytoprotection and Chemoprevention, Department of
Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, June 16, 2000.
125.
Amifostine: Mechanisms of Action, Portsmouth, New Hampshire, August 30, 2000.
126.
Amifostine: The Molecular Mechanisms of Action and Novel Roles in Cancer Treatment, DartmouthHitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, August 31, 2000.
127.
Amifostine (Ethyol): Mechanisms of Action and Novel Roles in Cancer Prevention and Treatment.
9th Meeting of the European Society for Pigment Cell Research, Perspectives for the Third
Millennium, University of Ulm, Ulm, Germany, September 30, 2000.
128.
Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Boston Medical
Center, Boston, Massachusetts, October 25, 2000.
129.
Ethyol Overview, New York Medical Group, Saggets Harbor, New York, October 26, 2000.
130.
Mechanisms Underlying the Anti-mutagenic and Anti-metastatic Effects of Amifostine, Cell and
Molecular Biology Graduate Program, Colorado State University, Fort Collins, Colorado, November
9, 2000.
131.
Radioprotection by Amifostine in Head and Neck Cancer, Tumor Board Conference, New Hampshire
Regional Medical Center, Nashau, New Hampshire, November 31, 2000.
132.
Mechanisms of Action of Amifostine (WR2721) as an Inhibitor of Metastases Development, Armed
Forces Radiobiology Research Institute, Bethesda, Maryland, January 5 , 2001.
133.
Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the
Management of Radiation-Induced Toxicities, Newport Beach, California, March 31, 2001.
134.
Mechanisms of Action of Amifostine, Department of Radiation Oncology, University of Maryland,
Baltimore, Maryland, April 3, 2001.
135.
Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the
Management of Radiation-Induced Toxicities, Chicago, Illinois, April 20, 2001.
136.
Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the
Management of Radiation-Induced Toxicities, Chicago, Illinois, April 27, 2001.
137.
Differential Activation of NFB, Gene Expression, and Protein Levels in Human Cells by Amifostine,
The First Investigators’ Congress on Radioprotection, St. Croix, US Virgin Islands, June 8, 2001.
30
Curriculum Vitae
David J. Grdina
138.
Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the
Management of Radiation-Induced Toxicities, Boston, Massachusetts, June 16, 2001.
139.
Inhibition of Spontaneous Metastases Formation by Amifostine, MedImmune Medical Advisory
Board Meeting, Sonoma, California, November 2, 2001.
140.
Radioprotectants: Current Status and New Directions, Symposium on: Evolving Approaches to
Improve Outcomes and Minimize Toxicities in Radiation Therapy, Ingenix Medical Education, San
Francisco, California, November 4, 2001.
141.
Chemopreventive and Anti-Metastatic Effects of Amifostine. MedImmune, Gaithersburg, Maryland,
January 9, 2002.
142.
Novel Applications of Amifostine in Cancer Therapy and Chemoprevention, University of Texas
Health Science Center at San Antonio, San Antonio, Texas, February 13, 2002.
143.
Antimetastatic Effects of Amifostine, MedImmune Oncology Cytoprotection Scientific Advisory
Board Meeting, Orlando, Florida, May 17, 2002.
144.
Antimetastatic Effects of Amifostine, The 2nd International Cytoprotection Investigators’ Congress,
St. Thomas, US Virgin Islands, June 7, 2002.
145.
Radiation Protectors, Sensitizers, and Combined Modality Therapies, The First Radiation Oncology
Residents Course, Department of Radiation Oncology, University of Maryland, Baltimore, Maryland,
August 24, 2002.
146.
Cellular Biology: Implications for the Concept of Chemoradioprotection, Symposium on
Chemoradioprotection in Lung Cancer: Cellular Biology, Physiology, and Clinical Update. Seton Hall
University School of Graduate Medical School Education, The American Academy of CME, and
Clinical Insights, Inc., ASTRO, New Orleans, Louisiana, October 5, 2002.
147.
MnSOD Mediated Delayed Radioprotective Effect in Tumor Cells Induced by Thiols. Tumor Biology
Seminar Series, Lombardi Cancer Center, Georgetown University, Washington D.C., November 15,
2002.
148.
Prevention of Mutagenesis by Phosphorothioates. Hollis-Eden Symposium on Radiation Protectors,
La Jolla, California, April 15, 2003.
149.
Mechanisms of Action Underlying Amifostine’s Anti-Metastatic Effect. Division of Radiation
Oncology Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, Texas,
April 23, 2003.
150.
MnSOD in Delayed Radiation Resistance. Department of Pathology and Laboratory Medicine,
Medical University of South Carolina, Charleston, South Carolina, November 17, 2003.
151.
Radioprotectors Workshop, Invited Participant, Radiation Oncology Sciences Program, National
Cancer Center, Bethesda, Maryland, December 3, 2003.
31
152.
Curriculum Vitae
David J. Grdina
Aminothiols Are Anti-Mutagenic and Anti-Carcinogenic and Mediate a Delayed Radioprotective
Effect. NASA Workshop on Solid Cancer Risks from Space Radiation, USRA, Center for Advanced
Space Studies, Houston, Texas, January 27, 2004.
153.
Radiation Response Modifiers Symposium Organizer and Discussion Leader, 51st Annual Meeting of
the Radiation Research Society, St. Louis, Missouri, April 24, 2004.
154.
Animal Models for Radiation Injury, Protection, and Therapy, Invited Participant, NIAID, Bethesda,
Maryland, May 26, 2004.
155.
ASA Conference on Radiation and Health: Radiation in Realistic Environments, Interactions Between
Radiation and Other Risk Modifiers: Radioprotectants: Current Status and New Directions, Beaver
Creek, Colorado, June 29, 2004.
156.
Blue Ribbon Panel for NIH Strategic Plan and Research Agenda for Medical Countermeasures
Against Radiological and Nuclear Threats, National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH): Radioprotectors, Bethesda, Maryland, October 14,
2004.
157.
Stereotactic Body Radiation Therapy: Clinical, Technical and Translational Aspects: Radioprotection
of Normal Tissue, Westin Galleria, Dallas, Texas, May 19, 2006.
158.
Prevention of Low Dose Radiation-Induced Genomic Instability with Clinically Relevant Non-Protein
Thiols, D.O.E. Contractors Meeting, Washington, D.C., August 1, 2006.
159.
Phosphorothioates-Genomic Stabilization-Prevention of Mutagenesis and Carcinogenesis, NCI/NIH
Workshop on Radiation Anti-Carcinogenesis, Workshop Chairperson, Washington, D.C., September
11, 2006.
160.
Classical Radioprotectors-The Phosphorothioates, NSBRI/NASA Radiation Medical
Countermeasures Workshop, League City, Texas, October 31, 2006.
161.
Thiol-Induced Adaptive Response in Normal and Malignant Tissues, First Symposium of the
Association for Ion-Beam Life Science: In Vivo Radiobiology in Cancer Research, NIRS, Chiba,
Japan, June 15, 2007.
162.
A Cellular MnSOD-Mediated Adaptive Response Induced by Amifostine, Seminar Series, Section of
Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern
Medical Center, Dallas Texas, Oct. 9, 2007.
163.
Thiol-Induced Delayed Radioprotective Effect and Its Implications in Radiation Oncology. Rodney
Withers Radiation Research Colloquium, David Geffen School of Medicine at UCLA, UCLA Jules
Stein Eye Institute, UCLA, Los Angeles, California, Oct. 27, 2007.
164.
Time, Dose, Fractionation. Department of Radiation Oncology. Residents’ Lecture, University of
Maryland, Baltimore, Maryland, Dec. 16, 2008.
165.
Prevention of Low Dose Radiation-Induced Genomic Instability with Clinically Relevant Non-Protein
Thiols and Vitamin E. Low Dose Radiation Research Investigators’ Workshop VIII, Department of
Energy Low Dose Radiation Program, Bethesda, Maryland, April 6, 2009.
32
Curriculum Vitae
David J. Grdina
166.
Time, Dose, Fractionation. Residents’ National Review Course, University of Maryland, Baltimore,
Maryland, May 29, 2009.
167.
Radiation Protectors and Sensitizers. Residents’ National Review Course, University of Maryland,
Baltimore, Maryland, May 29, 2009.
168.
Time, Dose, Fractionation. Department of Radiation Oncology. Residents’ Lecture, University of
Maryland, Baltimore, Maryland, January 26, 2010.
169.
Ethyol (Amifostine)-Mechanisms of Action and Novel Uses- Protection; Prevention; Anti-Metastases;
Stimulation of Endogenous Anti-Oxidants. Amifostine Drs. Working Group, Istanbul, Turkey, May 6,
2010.
170.
Ethyol (Amifostine)-Mechanisms of Action and Novel Uses- Protection; Prevention; Anti-Metastases;
Stimulation of Endogenous Anti-Oxidants. Amifostine Drs. Working Group, Athens, Greece, May 8,
2010.
171.
Ethyol (Amifostine)-Mechanisms of Action and Novel Uses. Drs. Working Group, Berlin, Germany,
October 25, 2010.
172.
Ethyol (Amifostine)-Mechanisms of Action and Novel Uses. Drs. Working Group, Paris, France,
October 26, 2010.
173.
Time, Dose, Fractionation. Resident’s National Review Course, University of Maryland, Baltimore,
Maryland, May 12, 2011.
174.
Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, Resident’s National Review
Course, University of Maryland, Baltimore, Maryland, May 13, 2011.
175.
LET and RBE, Resident’s National Review Course, University of Maryland, Baltimore, Maryland,
May 13, 2011.
176.
Time, Dose, Fractionation. Resident’s National Review Course, University of Maryland, Baltimore,
Maryland, May 5, 2012.
177.
Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, Resident’s National Review
Course, University of Maryland, May 6, 2012.
178.
LET and RBE, Resident’s National Review Course, University of Maryland, Baltimore, Maryland,
May 6, 2012.
179.
Time, Dose, Fractionation. University of Washington RadOnc Board Review Course, University of
Washington, Seattle, Washington, May 25, 2012.
180.
Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, University of Washington
RadOnc Board Review Course, University of Washington, Seattle, Washington, May 25, 2012.
181.
LET, RBE, and OER, University of Washington RadOnc Board Review Course, University of
Washington, Seattle, Washington, May 25, 2012.
33
Curriculum Vitae
David J. Grdina
34